Printer Friendly

MEDICAL GRAPHICS CLEARED TO MARKET BREAKTHROUGH LUNG DIAGNOSTIC SYSTEM:

MEDICAL GRAPHICS CLEARED TO MARKET BREAKTHROUGH LUNG DIAGNOSTIC SYSTEM:
 Begins Shipments
 ST. PAUL, Minn, Feb. 10 -- Medical Graphics Corporation (NASDAQ: MGCC) today announced that the U.S. Food and Drug Administration has issued marketing clearance for its PF/Dx, a new pulmonary (lung) function diagnostic system.
 The PF/Dx is the first complete pulmonary diagnostic system to provide true infection control through the use of disposable and easily- removable patient-contact components. The company began sales of the PF/Dx internationally in November 1991. Domestic shipments had been delayed pending FDA marketing clearance and will begin immediately.
 "Physicians and their patients have been asking for a complete pulmonary diagnostic lab that provides true infection control. They want a system that's portable, easy-to-use, quick, and accurate," said Catherine A. (Kye) Anderson, chairman, president and chief executive officer. "The PF/Dx is that system, and it will revolutionize pulmonary diagnostics."
 The PF/Dx uses the company's patented disposable pneumotach, a small device that accurately measures air flow; and a patented patient breathing circuit. Both components quickly snap on and off the system. Concern for cross-contamination between patients is eliminated.
 Physicians, respiratory therapists and other clinicians will use the PF/Dx to non-invasively diagnose the cause of shortness of breath and obstructive lung diseases such as asthma, emphysema, and bronchitis. The system will be used for monitoring these lung conditions, as well as lung cancer and AIDS-related pneumonia. The PF/Dx provides objective data to document the need for medication or surgery, and to measure its outcome.
 Designed for hospital labs, clinics and physicians' offices, the PF/Dx's compact-size and portability enable safe and thorough pulmonary function testing in virtually any location, such as patient bedside, satellite clinic or elsewhere within a facility.
 Medical Graphics Corporation develops computerized non-invasive cardiorespiratory diagnostic and monitoring systems for the early diagnosis, treatment and prevention of heart and lung disease. Since its founding in 1977, the company has pioneered every major technological breakthrough in cardiorespiratory diagnostics. With headquarters in St. Paul, Minnesota and Dusseldorf, Germany, Medical Graphics does business in more than 30 countries around the world.
 -0- 02/10/92
 /CONTACT: Marie Overfors of Medical Graphics, 612-484-4874/
 (MGCC) CO: Medical Graphics Corporation ST: Minnesota IN: MTC SU:


KH -- MN016 -- 8443 02/10/92 16:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1992
Words:379
Previous Article:DR PEPPER COMPANY DECLARES QUARTERLY DIVIDEND ON PREFERRED STOCK
Next Article:GREYHOUND FINANCIAL $750 MILLION SENIOR DEBT SHELF RATED 'A' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
MEDICAL GRAPHICS RECEIVES PATENT APPROVALS ON TWO DISPOSABLE PRODUCTS
MEDICAL GRAPHICS RECEIVES PATENT APPROVALS ON TWO DISPOSABLE PRODUCTS
MEDICAL GRAPHICS NAMES RUSSELL G. ACORN VICE PRESIDENT, RESEARCH AND DEVELOPMENT
MEDICAL GRAPHICS REPORTS BEST YEAR EVER, RECORD FOURTH QUARTER SALES
MEDICAL GRAPHICS CORPORATION SECURES NATIONAL GROUP PURCHASING CONTRACT
MEDICAL GRAPHICS CORPORATION RELEASES NEW EXERSCRIPT PRODUCT FOR FAT LOSS AND CARDIOVASCULAR CONDITIONING
MEDICAL GRAPHICS CORPORATION REPORTS80 PERCENT INCREASE IN FIRST QUARTER EARNINGS
MEDICAL GRAPHICS CORPORATION INTRODUCES PROGRAMMABLE CARDIO-KEY FOR CARDIAC REHABILITATION AND FITNESS
MEDICAL GRAPHICS CORPORATION AWARDED PURCHASING CONTRACT
MEDICAL GRAPHICS CORPORATION AWARDED PURCHASING CONTRACT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters